Crystal Structure of an FIV/HIV Chimeric Protease Complexed with the Broad-based Inhibitor, TL-3

Overview

Journal Retrovirology

Publisher Biomed Central

Specialty Microbiology

Date 2007 Jan 11

PMID 17212810

Citations 7

Authors

Holly Heaslet

Ying-Chuan Lin

Karen Tam

Bruce E Torbett

John H Elder

C David Stout

Affiliations

Soon will be listed here.

Abstract

We have obtained the 1.7 A crystal structure of FIV protease (PR) in which 12 critical residues around the active site have been substituted with the structurally equivalent residues of HIV PR (12X FIV PR). The chimeric PR was crystallized in complex with the broad-based inhibitor TL-3, which inhibits wild type FIV and HIV PRs, as well as 12X FIV PR and several drug-resistant HIV mutants 1234. Biochemical analyses have demonstrated that TL-3 inhibits these PRs in the order HIV PR > 12X FIV PR > FIV PR, with Ki values of 1.5 nM, 10 nM, and 41 nM, respectively 234. Comparison of the crystal structures of the TL-3 complexes of 12X FIV and wild-typeFIV PR revealed theformation of additinal van der Waals interactions between the enzyme inhibitor in the mutant PR. The 12X FIV PR retained the hydrogen bonding interactions between residues in the flap regions and active site involving the enzyme and the TL-3 inhibitor in comparison to both FIV PR and HIV PR. However, the flap regions of the 12X FIV PR more closely resemble those of HIV PR, having gained several stabilizing intra-flap interactions not present in wild type FIV PR. These findings offer a structural explanation for the observed inhibitor/substrate binding properties of the chimeric PR.

Citing Articles

Dimer Interface Organization is a Main Determinant of Intermonomeric Interactions and Correlates with Evolutionary Relationships of Retroviral and Retroviral-Like Ddi1 and Ddi2 Proteases.

Motyan J, Miczi M, Tozser J Int J Mol Sci. 2020; 21(4).

PMID: 32079302 PMC: 7072860. DOI: 10.3390/ijms21041352.

Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors.

Lin Y, Happer M, Elder J J Virol. 2013; 87(15):8524-34.

PMID: 23720716 PMC: 3719837. DOI: 10.1128/JVI.01240-13.

Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.

Li M, Gustchina A, Matuz K, Tozser J, Namwong S, Goldfarb N FEBS J. 2011; 278(22):4413-24.

PMID: 21951660 PMC: 3500906. DOI: 10.1111/j.1742-4658.2011.08364.x.

Accessory mutations maintain stability in drug-resistant HIV-1 protease.

Chang M, Torbett B J Mol Biol. 2011; 410(4):756-60.

PMID: 21762813 PMC: 3139113. DOI: 10.1016/j.jmb.2011.03.038.

Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease.

Lin Y, Perryman A, Olson A, Torbett B, Elder J, Stout C Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 6):540-8.

PMID: 21636894 PMC: 3107052. DOI: 10.1107/S0907444911011681.

References

Beck Z, Morris G, Elder J . Defining HIV-1 protease substrate selectivity. Curr Drug Targets Infect Disord. 2002; 2(1):37-50. DOI: 10.2174/1568005024605837. View

Buhler B, Lin Y, Morris G, Olson A, Wong C, Richman D . Viral evolution in response to the broad-based retroviral protease inhibitor TL-3. J Virol. 2001; 75(19):9502-8. PMC: 114517. DOI: 10.1128/JVI.75.19.9502-9508.2001. View

Lee T, Laco G, Torbett B, Fox H, Lerner D, Elder J . Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. Proc Natl Acad Sci U S A. 1998; 95(3):939-44. PMC: 18632. DOI: 10.1073/pnas.95.3.939. View

Lin Y, Beck Z, Lee T, Le V, Morris G, Olson A . Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease. J Virol. 2000; 74(10):4710-20. PMC: 111993. DOI: 10.1128/jvi.74.10.4710-4720.2000. View

Elder J, Dean G, Hoover E, Hoxie J, Malim M, Mathes L . Lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 1998; 14(9):797-801. DOI: 10.1089/aid.1998.14.797. View

Pettit S, Lindquist J, Kaplan A, Swanstrom R . Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology. 2005; 2:66. PMC: 1291402. DOI: 10.1186/1742-4690-2-66. View

Mak C, Le V, Lin Y, Elder J, Wong C . Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue. Bioorg Med Chem Lett. 2001; 11(2):219-22. DOI: 10.1016/s0960-894x(00)00641-7. View

Martin P, Vickrey J, Proteasa G, Jimenez Y, Wawrzak Z, Winters M . "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. Structure. 2005; 13(12):1887-95. DOI: 10.1016/j.str.2005.11.005. View

Mak C, Brik A, Lerner D, Elder J, Morris G, Olson A . Design and synthesis of broad-based mono- and bi- cyclic inhibitors of FIV and HIV proteases. Bioorg Med Chem. 2003; 11(9):2025-40. DOI: 10.1016/s0968-0896(03)00054-3. View

10.

Pettit S, Sheng N, Tritch R, Swanstrom R . The regulation of sequential processing of HIV-1 Gag by the viral protease. Adv Exp Med Biol. 1998; 436:15-25. DOI: 10.1007/978-1-4615-5373-1_2. View

11.

Le V, Mak C, Lin Y, Elder J, Wong C . Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine. Bioorg Med Chem. 2001; 9(5):1185-95. DOI: 10.1016/s0968-0896(00)00346-1. View

12.

Lin Y, Brik A, de Parseval A, Tam K, Torbett B, Wong C . Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system. J Virol. 2006; 80(16):7832-43. PMC: 1563824. DOI: 10.1128/JVI.00374-06. View

13.

Heaslet H, Kutilek V, Morris G, Lin Y, Elder J, Torbett B . Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3. J Mol Biol. 2006; 356(4):967-81. DOI: 10.1016/j.jmb.2005.11.094. View

14.

Toth G, Borics A . Flap opening mechanism of HIV-1 protease. J Mol Graph Model. 2005; 24(6):465-74. DOI: 10.1016/j.jmgm.2005.08.008. View

15.

Lai C, Harris B, Cook P . Mechanism of activation of the NAD-malic enzyme from Ascaris suum by fumarate. Arch Biochem Biophys. 1992; 299(2):214-9. DOI: 10.1016/0003-9861(92)90266-y. View

16.

Brunger A, Adams P, Clore G, DeLano W, Gros P, Grosse-Kunstleve R . Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr. 1998; 54(Pt 5):905-21. DOI: 10.1107/s0907444998003254. View

17.

Jones T, Zou J, Cowan S, Kjeldgaard M . Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A. 1991; 47 ( Pt 2):110-9. DOI: 10.1107/s0108767390010224. View

18.

Liu F, Kovalevsky A, Louis J, Boross P, Wang Y, Harrison R . Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. J Mol Biol. 2006; 358(5):1191-9. DOI: 10.1016/j.jmb.2006.02.076. View

19.

Lin Y, Lin X, Hong L, Foundling S, Heinrikson R, Thaisrivongs S . Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry. 1995; 34(4):1143-52. DOI: 10.1021/bi00004a007. View

20.

Vagin A, Teplyakov A . An approach to multi-copy search in molecular replacement. Acta Crystallogr D Biol Crystallogr. 2000; 56(Pt 12):1622-4. DOI: 10.1107/s0907444900013780. View